Inicio・Lista de Acciones・Innoviva Inc

Innoviva Inc

Cerrado

SectorSanidad

20.42 -3.13

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

20.11

Máximo

20.97

Métricas clave
By Trading Economics
Ingresos	-55M 187M
Ventas	-20M 98M
P/B Media del Sector	3.318 68.51
BPA	0.47
Margen de beneficios	190.415
Empleados	159
EBITDA	31M 239M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+92.66% upside

Dividendos
By Acuity
Próximas Ganancias	11 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-169M 1.5B
Apertura anterior	23.55
Cierre anterior	20.42

Innoviva Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 ago 2026, 21:01 UTC

Innoviva Inc shares are lower in after-market hours, reflecting a decline since Friday's close and trading near the lower end of their one-month range.

6 ago 2026, 19:51 UTC

News

Innoviva Inc shares are higher as the company shifts to a diversified healthcare model, supported by $773 million in investments and positive momentum since Wednesday.

5 ago 2026, 21:01 UTC

Innoviva Inc shares are trading higher in after-market hours, recovering from a session low. No specific news was identified to explain the movement.

3 ago 2026, 19:46 UTC

News

Innoviva Inc shares are lower today, continuing a downward trend. Analysts from BTIG and HC Wainwright maintain buy ratings with targets of $42.00 and $46.00.

31 jul 2026, 20:06 UTC

Shares of Innoviva Inc. are trading lower, continuing a downward trend. The stock remains below its 20-day moving average amid no specific news.

30 jul 2026, 19:02 UTC

Innoviva Inc shares are declining amid market weakness and rising jobless claims. The stock remains near the lower end of its one-month range.

29 jul 2026, 19:06 UTC

Macro Event

Innoviva Inc shares are lower today as market scrutiny increases following the Federal Reserve's decision to maintain interest rates amid ongoing geopolitical tensions.

28 jul 2026, 20:03 UTC

Innoviva Inc shares are higher today, continuing an upward trend since Monday. No specific news was identified to explain the price movement.

27 jul 2026, 19:56 UTC

Innoviva Inc shares are lower today, reflecting broader market trends amid a significant drop in oil prices. No specific company news was identified.

21 jul 2026, 15:46 UTC

Innoviva Inc shares are higher today, reflecting a broader trend in rising equity indices. The stock remains below its 20-day moving average.

20 jul 2026, 18:31 UTC

Innoviva Inc shares are lower today, reflecting broader weakness in the Pharmaceuticals sub-sector. The stock has reversed from a recent trend of higher closes.

Comparación entre iguales

Cambio de precio

Innoviva Inc previsión

Precio Objetivo

By TipRanks

92.66% repunte

Estimación a 12 Meses

Media 40.67 USD 92.66%

Máximo 46 USD

Mínimo 34 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Innoviva Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.